Drug Overview
Cabotegravir is an integrase strand transfer inhibitor analog of Tivicay (dolutegravir; ViiV Healthcare), and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), branded as Edurant (Johnson & Johnson).
Cabotegravir/rilpivirine is anticipated to be the first long-acting injectable (LAI) to enter the HIV market, and has demonstrated non-inferiority to standard-of-care three-drug regimens in virologically suppressed patients. the author expects uptake to be primarily driven by patients who would favor the LAI over a once-daily oral drug. Indeed, key opinion leaders have reported that a minority of patients are eager to receive dosing once every four weeks and possibly once every eight weeks in order to avoid a daily reminder of their HIV infection and the associated stigma. However, while ViiV Healthcare and Johnson & Johnson are expected to tout the LAI as an attractive option for patients with poor adherence to their existing once-daily treatment regimen, key opinion leaders have voiced concerns over this approach due to the increased potential for resistance generation if patients are also poorly adherent to the LAI.
Cabotegravir is an integrase strand transfer inhibitor analog of Tivicay (dolutegravir; ViiV Healthcare), and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), branded as Edurant (Johnson & Johnson).
Cabotegravir/rilpivirine is anticipated to be the first long-acting injectable (LAI) to enter the HIV market, and has demonstrated non-inferiority to standard-of-care three-drug regimens in virologically suppressed patients. the author expects uptake to be primarily driven by patients who would favor the LAI over a once-daily oral drug. Indeed, key opinion leaders have reported that a minority of patients are eager to receive dosing once every four weeks and possibly once every eight weeks in order to avoid a daily reminder of their HIV infection and the associated stigma. However, while ViiV Healthcare and Johnson & Johnson are expected to tout the LAI as an attractive option for patients with poor adherence to their existing once-daily treatment regimen, key opinion leaders have voiced concerns over this approach due to the increased potential for resistance generation if patients are also poorly adherent to the LAI.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
